PDF(Pubmed)
Abstract：
There is a serious worldwide health problem caused by chronic kidney disease (CKD), yet there are few viable therapies. Therapeutic promise in the treatment of chronic kidney disease (CKD) has been shown by the use of the traditional Chinese herbal compound Shengyang Yiwei Decoction (SYD). However, the chemical processes through which SYD exerts its effects are still unknown. The purpose of this network pharmacology research is to better understand the molecular mechanism of action of Shengyang Yiwei Decoction (SYD) in the treatment of chronic kidney disease (CKD). Traditional Chinese Medicine Systems Pharmacology (TCMSP) was first searched for information on the chemical components of Shengyang Yiwei Decoction. The molecular targets of SYD were then predicted using the Pharm Mapper service. After that, we used databases like DIG-SEE, TTD, and OMIM to zero down on the targets most closely linked to CKD. Cytoscape 3.2.1 was used to generate the component-target network representing SYD\'s therapy of CKD. In addition, KEGG signal pathways and GO biological processes were analyzed using the DAVID database, and the findings were displayed via OmicShare Tools. Twenty-two active components were isolated from Shengyang Yiwei Decoction, and they were linked to 36 therapeutic targets for CKD in the current investigation. According to the results of the network pharmacology study, 41 signaling pathways are involved in mediating the therapeutic effects of SYD. In addition, SYD\'s broad therapeutic impact in CKD therapy was shown to include 29 molecular activities, 14 cell components, and 91 biological processes. This research utilizes a multivariate analysis to provide light on the strategies and outcomes of treating CKD using Shengyang Yiwei Decoction. Clinical therapeutic methods for CKD management may benefit greatly from a thorough knowledge of the underlying processes and material foundation of this disease.
摘要：
慢性肾脏病（CKD）引起了严重的全球健康问题，然而，几乎没有可行的治疗方法。中药复方升阳益胃汤（SYD）已显示出治疗慢性肾脏病（CKD）的治疗前景。然而,SYD发挥其作用的化学过程仍然未知。本网络药理学研究旨在更好地了解升阳益胃汤(SYD)治疗慢性肾脏病(CKD)的分子作用机制。首次搜索中药系统药理学（TCMSP）有关升阳益胃汤化学成分的信息。然后使用PharmMapper服务预测SYD的分子靶标。之后,我们使用了DIG-SEE这样的数据库,TTD,和OMIM将与CKD最密切相关的目标归零。Cytoscape3.2.1用于生成代表SYD治疗CKD的组分靶网络。此外,使用DAVID数据库分析KEGG信号通路和GO生物过程，调查结果是通过OmicShare工具显示的。从升阳益胃汤中分离出22个活性成分，在目前的研究中,它们与36个CKD治疗靶点相关.根据网络药理学研究的结果,41个信号通路参与介导SYD的治疗效果。此外,SYD在CKD治疗中的广泛治疗作用被证明包括29种分子活性，14个细胞组件，和91个生物过程。本研究采用多变量分析，为升阳益胃汤治疗CKD的策略和结果提供依据。CKD管理的临床治疗方法可能会从对这种疾病的基本过程和物质基础的全面了解中受益匪浅。
